论文部分内容阅读
临床试验表明 ,抗CD2 0抗体 1F5、C2B8和抗B1对B细胞淋巴瘤有较好的疗效。C2B8已投放市场 ,该抗体对非霍奇金淋巴瘤的有效率达 50 %～ 60 %。131碘 (131I)标记的抗B1和90 钇 (90 Y)标记的C2B8的总有效率为 72 %～ 1 0 0 % ,完全缓解率为 3 0 %～ 4 0 %。最新的研究发现 ,将抗CD2 0抗体与抗生蛋白链菌素 (Streptavidin)结合 ,再结合放射性生物素分子可以提高疗效。另一种新方法是利用携带嵌合体抗CD2 0抗体的自体细胞毒性T淋巴细胞 ,通过转染抗CD2 0抗体分子的融合基因 ,从而使T淋巴细胞特异地杀伤淋巴瘤细胞。
Clinical trials have shown that anti-CD20 antibodies 1F5, C2B8 and anti-B1 have a good effect on B-cell lymphoma. C2B8 has been marketed and the antibody has an efficiency of 50% to 60% for non-Hodgkin’s lymphoma. The total effective rate of 131I-labeled anti-B1 and 909090Y-labeled C2B8 was 72% to 100%, and the complete response rate was 30% to 40%. Recent studies have found that combining anti-CD20 antibodies with Streptavidin and combining radioactive biotin molecules can improve efficacy. Another new method is the use of autologous cytotoxic T lymphocytes carrying chimeric anti-CD20 antibodies by transfecting fusion genes of anti-CD20 antibody molecules, so that T lymphocytes specifically kill lymphoma cells.